FDA Testosterone Panel: Are We Finally Done With Fear-Based TRT Policy?

In December 2025, the FDA convened an expert panel to reexamine how testosterone replacement therapy (TRT) is labeled, regulated, and discussed in men’s healthcare.

For decades, testosterone has been burdened by warnings and restrictions that were never fully supported by data. Those policies didn’t just shape regulation. They shaped how doctors practice, how patients are counseled, and whether men get timely care at all.

TRT has lived in a gray area for years, and that hasn’t been harmless. 

We see it all the time: Fear-based policy delays diagnosis, creates confusion, and keeps men from getting care that could meaningfully improve their quality of life. Testosterone is widely prescribed and clearly beneficial for many men, yet it’s still treated with unnecessary suspicion.

We’re breaking down what actually came out of the FDA testosterone panel held in December 2025 and what it means if you’re considering testosterone therapy or already using it. And if you want to hear the full discussion firsthand, you can watch the complete session after reading.

What Was the FDA Testosterone Panel?

The FDA testosterone panel brought together experts in urology, sexual medicine, endocrinology, and men’s health to review how testosterone replacement therapy is currently labeled and regulated. 

It wasn’t about whether testosterone “works,” since that question has been answered. It was about whether decades-old warnings still reflect modern data or whether they’ve been standing in the way of appropriate care.

Panelists were asked to revisit long-standing concerns around prostate cancer, cardiovascular risk, and who should even be allowed to receive TRT. The conclusion was clear: Much of the existing TRT policy does not align with modern data or clinical practice.

That may sound new at the regulatory level, but it reflects what we have been seeing for years. Science has moved a lot faster than policy, and this panel was long overdue.

Why Is There a Testosterone Stigma?

Testosterone didn’t earn its stigma through evidence. It inherited it.

It’s been culturally linked to gyms, “meatheads,” and steroid abuse—then further distorted by the false idea that low T automatically means ED. It doesn’t. They can overlap, but they aren’t mutually exclusive.

That perception created real consequences: men stopped talking about symptoms, labs were downplayed, and many were discouraged from seeking care. Too often, primary care treats low testosterone as “not a real issue.” Over time, the narrative hardened into training and labeling that still influences care today—despite the science.

The FDA testosterone panel called out this disconnect between outdated beliefs and the reality that testosterone is a vital health marker that should be evaluated, not dismissed.

Does Testosterone Increase Prostate Cancer Risk?

Prostate cancer has been one of the most persistent fears tied to TRT, so it was a central topic during the FDA testosterone panel.

According to panel expert Dr. Abraham Morgentaler, Harvard urologist and pioneer researcher on testosterone and prostate cancer:

• Testosterone is not a carcinogen.
• Modern data does not show increased prostate cancer risk with properly monitored TRT.
• Long-standing contraindications are based on outdated assumptions.

Despite this, FDA labeling still includes warnings that suggest TRT is unsafe for men with prostate cancer or even suspected prostate cancer. Panelists argued that these warnings are not supported by contemporary evidence and unnecessarily discourage appropriate care.

We’ve seen many patients who were scared out of treating their low testosterone symptoms after discussing it with a primary care doctor because the old narrative still gets repeated: TRT equals prostate cancer risk.

Evidence-based medicine requires a willingness to update beliefs as new data emerges.

Is TRT Safe for the Heart? What the FDA Testosterone Panel Said

Heart risk has been another loud warning attached to testosterone for years. For many men, it was the reason they were told TRT simply wasn’t worth the risk. The TRAVERSE trial changed that conversation.

With over 5,000 men followed, including those with existing cardiovascular risk, the study found no increase in major cardiac events with testosterone therapy.

When the FDA removed the cardiovascular black box warning in early 2025, it acknowledged what the data had already shown. The December FDA panel reinforced that point: appropriate screening and monitoring matter far more than fear-based avoidance.

Here are some key points from the TRAVERSE trial:

• Over 5,200 men aged 45 to 80 were followed.
• Participants had existing or high cardiovascular risk.
• Rates of major cardiac events were similar between testosterone and placebo groups.

Why Is Testosterone Still a Controlled Substance?

Testosterone’s classification as a Schedule III controlled substance wasn’t designed with patient care in mind. It was a response to illicit steroid abuse, not evidence-based testosterone therapy.

Decades later, that classification still shapes how testosterone is perceived and accessed. And when legitimate care becomes hard to obtain, men don’t stop looking for answers. They just find them elsewhere, often without proper oversight.

That’s how you end up with fragmented care, poor oversight, and unnecessary TRT risk. According to panel experts, Schedule III status contributes to:

• Increased stigma around testosterone therapy
• Limited access through traditional medical channels (and difficulty maintaining a steady supply of medication) 
• Growth of unregulated alternatives

Who Is TRT Meant For? FDA Labels vs. Medical Guidelines

One of the most frustrating realities for patients is being told two conflicting things at once: your symptoms and labs qualify you for TRT, but the FDA says otherwise. Currently, TRT approval is limited to men whose low testosterone is caused by specific disorders of the testes or brain. 

Right now, testosterone policy doesn’t reflect how low T shows up in real life. Men can feel the symptoms, see it in their labs, and still hit roadblocks because the official labeling hasn’t caught up.

Panelists called on the FDA to update testosterone indications so physicians can focus on treating patients, not navigating outdated rules that no longer match the science.

What the FDA Testosterone Panel Means for Men

The FDA testosterone panel probably won’t bring immediate policy changes, but it marks an important shift in tone and direction. For men already on TRT, this discussion validates what evidence-based clinics like Victory Men’s Health have practiced for years. 

For men considering therapy, it offers reassurance that many of the fears surrounding testosterone are being reevaluated. Here’s what it means in practical terms:

• Testosterone deficiency is increasingly recognized as a legitimate health issue
• Fear-based barriers to care are being challenged
• Individualized, symptom-based treatment remains essential

The message from the panel was one we wholeheartedly agree with: testosterone therapy should be guided by evidence, not stigma.

It’s Time to Abandon Fear-Based TRT Policy

While regulatory change takes time, it’s clear that many of the fears that shaped TRT policy for decades are no longer supported by current evidence. Testosterone deficiency is a real medical condition that affects your health, quality of life, and long-term outcomes. 

At Victory Men’s Health, this science-first approach has always guided our care. We prioritize symptom-based evaluation and personalized treatment plans designed to support long-term health.